PDGFRA Antibody for Soft Tissue Sarcoma

Lillian R. Klug, Michael Heinrich

    Research output: Contribution to journalShort survey

    4 Citations (Scopus)

    Abstract

    Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.

    Original languageEnglish (US)
    Pages (from-to)555
    Number of pages1
    JournalCell
    Volume168
    Issue number4
    DOIs
    StatePublished - Feb 9 2017

    Fingerprint

    Sarcoma
    Tissue
    Antibodies
    Chemotherapy
    Doxorubicin
    Tumors
    Phosphotransferases
    Chemical activation
    Monoclonal Antibodies
    Ligands
    Drug Therapy
    Growth
    olaratumab
    Neoplasms

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    PDGFRA Antibody for Soft Tissue Sarcoma. / Klug, Lillian R.; Heinrich, Michael.

    In: Cell, Vol. 168, No. 4, 09.02.2017, p. 555.

    Research output: Contribution to journalShort survey

    Klug, Lillian R. ; Heinrich, Michael. / PDGFRA Antibody for Soft Tissue Sarcoma. In: Cell. 2017 ; Vol. 168, No. 4. pp. 555.
    @article{9adf8e7aed034f9a86122b29533b1ffd,
    title = "PDGFRA Antibody for Soft Tissue Sarcoma",
    abstract = "Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.",
    author = "Klug, {Lillian R.} and Michael Heinrich",
    year = "2017",
    month = "2",
    day = "9",
    doi = "10.1016/j.cell.2017.01.028",
    language = "English (US)",
    volume = "168",
    pages = "555",
    journal = "Cell",
    issn = "0092-8674",
    publisher = "Cell Press",
    number = "4",

    }

    TY - JOUR

    T1 - PDGFRA Antibody for Soft Tissue Sarcoma

    AU - Klug, Lillian R.

    AU - Heinrich, Michael

    PY - 2017/2/9

    Y1 - 2017/2/9

    N2 - Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.

    AB - Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.

    UR - http://www.scopus.com/inward/record.url?scp=85012066311&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85012066311&partnerID=8YFLogxK

    U2 - 10.1016/j.cell.2017.01.028

    DO - 10.1016/j.cell.2017.01.028

    M3 - Short survey

    C2 - 28187274

    AN - SCOPUS:85012066311

    VL - 168

    SP - 555

    JO - Cell

    JF - Cell

    SN - 0092-8674

    IS - 4

    ER -